Garrett Winslow Biography and Net Worth

General Counsel of Damora Therapeutics, Inc. Common Stock

Presently, Garrett M. Winslow holds the position of Senior Vice President & General Counsel of Galecto, Inc.

In his past career he was Principal at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC and Secretary, Vice President-Legal & General Counsel at Spring Bank Pharmaceuticals, Inc.

Garrett M. Winslow received a graduate degree from Boston University School of Law, a graduate degree from Suffolk University Law School and an undergraduate degree from the University of Washington.

How do I contact Garrett Winslow?: The corporate mailing address for Mr. Winslow and other Damora Therapeutics, Inc. Common Stock executives is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. Damora Therapeutics, Inc. Common Stock can also be reached via phone at 45-7070-5210 and via email at [email protected]. Learn More on Garrett Winslow's contact information.
Has Garrett Winslow been buying or selling shares of Damora Therapeutics, Inc. Common Stock?: Garrett Winslow has not been actively trading shares of Damora Therapeutics, Inc. Common Stock during the last quarter. Most recently, on Friday, December 3rd, Garrett Winslow bought 80 shares of Damora Therapeutics, Inc. Common Stock stock. The stock was acquired at an average cost of $62.00 per share, with a total value of $4,960.00. Learn More on Garrett Winslow's trading history.
Who are Damora Therapeutics, Inc. Common Stock's active insiders?: Damora Therapeutics, Inc. Common Stock's insider roster includes Jonathan Freve (CFO), Bertil Lindmark (Insider), Hans Schambye (CEO), and Garrett Winslow (General Counsel). Learn More on Damora Therapeutics, Inc. Common Stock's active insiders.
Are insiders buying or selling shares of Damora Therapeutics, Inc. Common Stock?: In the last year, insiders at the sold shares 4 times. They sold a total of 1,717 shares worth more than $20,838.98. The most recent insider tranaction occured on January, 2nd when CEO Hans T Schambye sold 700 shares worth more than $14,966.00. Insiders at Damora Therapeutics, Inc. Common Stock own 10.5% of the company. Learn More about insider trades at Damora Therapeutics, Inc. Common Stock.
Information on this page was last updated on 1/2/2026.

Garrett Winslow Insider Trading History at Damora Therapeutics, Inc. Common Stock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/3/2021	Buy	80	$62.00	$4,960.00

Garrett Winslow Buying and Selling Activity at Damora Therapeutics, Inc. Common Stock

Damora Therapeutics, Inc. Common Stock Company Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Today's Range

Now: $25.82

$25.55

$27.88

50 Day Range

MA: $26.81

$18.14

$32.30

2 Week Range

Now: $25.82

$2.14

$38.33

Volume

287,217 shs

Average Volume

276,563 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield